Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in white patients with high myopia

Monica Ravenstijn, Caroline C.W. Klaver, Suzanne Yzer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
46 Downloads (Pure)


Purpose:To report long-term treatment outcomes of intravitreal bevacizumab in myopic macular neovascularization (MNV).Methods:Retrospective analysis of longitudinal, clinical data of patients with high myopic MNV treated with intravitreal bevacizumab. One-hundred and seventeen eyes of 106 patients were followed from first injection up to 12 years. Outcome measures were best-corrected visual acuity change during follow-up and myopic MNV recurrence.Results:Mean (±SD) baseline best-corrected visual acuity (0.56 ± 0.46 logMAR, 20/80) significantly improved after first treatment (0.33 ± 0.33, 20/50, P < 0.001). At 4 years (n = 86), best-corrected visual acuity was no longer significantly better than at baseline (0.55 ± 0.57, P = 0.30) and continued to deteriorate to 0.84 ± 0.76 (20/125) at 10 years (n = 27). Of the 27 eyes (23%) who reached 10 years of follow-up, 53% developed MNV-related chorioretinal atrophy. The cumulative incidence of recurrent myopic MNV was 34% at 2 years and 59% at 5 years. Best-corrected visual acuity decrease in eyes with or without recurrent MNV was similar (P = 0.58). Patchy chorioretinal atrophy (hazard ratio 3.0, P = 0.02) and subfoveal MNVs (hazard ratio 2.5, P = 0.048) were significantly associated with recurrent MNV.Conclusion:This retrospective myopic MNV study revealed that visual improvement after intravitreal bevacizumab injections was not maintained over time. Macular neovascularization recurrences occurred frequently but did not alter the already poor visual prognosis.

Original languageEnglish
Pages (from-to)444-453
Number of pages10
Issue number3
Publication statusPublished - 1 Mar 2023

Bibliographical note

Funding Information:
Supported by Oogfonds, Landelijke Stichting voor Blinden en Slechtzienden, Algemene Nederlandse Vereniging Ter Voorkoming Van Blindheid and Stichting Beheer ‘t Schild through Uitzicht (2019-14), Rotterdamse Stichting Blindenbelangen (20190034), and Stichting Wetenschappelijk Onderzoek Oogziekenhuis (2019S06). C. C. W. Klaver obtained funding from Netherlands Organization for Scientific Research (NWO, Grant 91815655), and from European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant 648268).

Publisher Copyright:
Copyright © by Ophthalmic Communications Society, Inc.

Cite this